Centauri Therapeutics Overview
- Founded
- 2014

- Status
- Private
- Employees
- 10

- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $2.14M

- Investors
- 5
Centauri Therapeutics General Information
Description
Operator of biotechnology company intended to discover and develop novel molecules targeting life threatening diseases. The company's biotechnology service uses alphamer technology in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections, enabling doctors to treat infectious diseases.
Contact Information
- Discovery Park
- Kent CT13 9ND
- England, United Kingdom
Centauri Therapeutics Timeline
Centauri Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
4. Early Stage VC | 01-Dec-2018 | $2.14M | 00.000 | 000.00 | Completed | Generating Revenue |
3. Accelerator/Incubator | 11-Sep-2017 | 00.000 | 00.000 | Completed | Generating Revenue | |
2. Early Stage VC | 20-Feb-2017 | $3.13M | $6.11M | Completed | Generating Revenue | |
1. Early Stage VC | 21-Dec-2016 | $2.99M | $2.99M | 000.00 | Completed | Startup |
Centauri Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 00.000 | |
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
Ordinary | 00 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
Ordinary | 0,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
Ordinary | 000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
Ordinary | 1,245 | $0.003109 | $310.73 | $310.73 | 1x | $310.73 | 1.92% | |
Ordinary | 519 | $0.003109 | $310.58 | $310.58 | 1x | $310.58 | 0.8% |
Centauri Therapeutics Comparisons
Industry
00000000
0000000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialCentauri Therapeutics Competitors (14)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Apeptico Forschung und Entwicklung | Venture Capital-Backed | Vienna, Austria | 00.000 | 0000000000 | 00.000 | |
0000000 | Venture Capital-Backed | Houston, TX | 00 | 000.00 | 000000000 - | 000.00 |
000000 | Venture Capital-Backed | Cambridge, United Kingdom | 00 | 00000 | 0000000000 0 | 00000 |
00000000 | Venture Capital-Backed | San Carlos, CA | 00 | 00000 | 00000000000 | 00000 |
0000000 0000000000 | Formerly VC-backed | Cambridge, United Kingdom | 00 | 00000 | 000000000 | 00000 |
Centauri Therapeutics Executive Team (2)
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Michael Westby Ph.D | Board Member & Chief Executive Officer | ||
Stuart Lawson | Board Member & Chief Financial Officer |
Centauri Therapeutics Board Members (5)
Name | Representing | Role | Since |
---|---|---|---|
Clive Dix Ph.D | Self | Chairman | 000 0000 |
Jonathan Synett | NCL Technology Ventures | Board Member | 000 0000 |
Michael Westby Ph.D | Centauri Therapeutics | Board Member & Chief Executive Officer | 000 0000 |
Stuart Lawson | Self | Board Member & Chief Financial Officer | 000 0000 |
Centauri Therapeutics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialCentauri Therapeutics Investors (5)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Innovate UK | Government | 000 0000 | 000000 0 | ||
Animatrix Capital | Venture Capital | Minority | 000 0000 | 000000 0 | |
Discovery Park | Other | Minority | 000 0000 | 000000 0 | |
NCL Technology Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
Renaissance Capital Partners | Growth/Expansion | Minority | 000 0000 | 000000 0 |
Centauri Therapeutics Investments (2)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
00000000 000000000 | 02-Mar-2016 | 00000 0000000 | 00000 | Drug Discovery | 0000000 000000 00.0 |
Altermune Technologies | 18-Jan-2016 | Buyout/LBO | Therapeutic Devices | 0000000 000000 00.0 |